Show simple item record

dc.creatorJančić, Ivan
dc.creatorArsenović-Ranin, Nevena
dc.creatorSefik-Bukilica, Mirjana
dc.creatorŽivojinović, Slađana
dc.creatorDamjanov, Nemanja
dc.creatorSpasovski, Vesna
dc.creatorSrzentić, Sanja
dc.creatorStanković, Biljana
dc.creatorPavlović, Sonja
dc.date.accessioned2019-09-02T11:36:32Z
dc.date.available2019-09-02T11:36:32Z
dc.date.issued2013
dc.identifier.issn0172-8172
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1998
dc.description.abstractTo examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.en
dc.publisherSpringer Heidelberg, Heidelberg
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175050/RS//
dc.rightsrestrictedAccess
dc.sourceRheumatology International
dc.subject-174G/C IL-6 polymorphismen
dc.subjectRheumatoid arthritisen
dc.subjectEtanercepten
dc.subjectDAS28 improvementen
dc.title-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritisen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractСпасовски, Весна; Сефик-Букилица, Мирјана; Aрсеновић-Ранин, Невена; Срзентић, Сања; Дамјанов, Немања; Јанчић, Иван; Станковић, Биљана; Павловић, Соња; Живојиновић, Слађана;
dc.citation.volume33
dc.citation.issue6
dc.citation.spage1481
dc.citation.epage1486
dc.citation.other33(6): 1481-1486
dc.citation.rankM23
dc.identifier.wos000319517000017
dc.identifier.doi10.1007/s00296-012-2586-y
dc.identifier.pmid23233117
dc.identifier.scopus2-s2.0-84878678926
dc.identifier.rcubconv_2858
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record